Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721884 · ClinicalTrials.gov registry record · Phase 1
Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth
A Phase 1 study of Small Intestinal Bacterial Overgrowth Syndrome (SIBO), sponsored by National University of Natural Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06721884: Recruiting Phase 1 study of Small Intestinal Bacterial Overgrowth Syndrome (SIBO), sponsored by National University of Natural Medicine.
NCT06721884 is a Phase 1 study of Small Intestinal Bacterial Overgrowth Syndrome (SIBO) that is actively recruiting participants, run by National University of Natural Medicine. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06721884, a Phase 1 study of Small Intestinal Bacterial Overgrowth Syndrome (SIBO), is actively recruiting participants, sponsored by National University of Natural Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \*E. coli\* and \*Klebsiella\*, which are linked to a type of SIBO that produces hydrogen gas. This study aims to test if Artemisia annua is safe and well-tolerated for adults with hydrogen-type SIBO. Over five weeks, participants will take either 5 grams of dried Artemisia annua leaves or a placebo. Researchers will monitor safety through blood tests, vital signs, and adverse events, and they will assess symptom changes using questionnaires and breath tests. The trial will include up to 32 participants from the Portland, Oregon area. Participants will be randomly assigned to treatment groups, and neither they, the researchers, nor the test administrators will know who is receiving the herb or the placebo. Results will be analyzed using standard statistical methods. This study addresses the lack of research on herbal treatments for SIBO. If successful, the findings could lead to larger studies and help expand treatment options for people with SIBO.
Primary Outcome
RBC, WBC, platelets
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT Artemisia Annua Leaf
Study Locations (1)
Oregon
- Helfgott Research Institute - National University of Natural Medicine - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What NCT06721884 shows while recruiting
NCT06721884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Small Intestinal Bacterial Overgrowth Syndrome (SIBO) appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06721884 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06721884 about?
NCT06721884 is a clinical study titled "Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth". Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address thi...
What is the current status of trial NCT06721884?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-01-01. Estimated completion is 2026-01.
What conditions does trial NCT06721884 study?
This clinical trial studies the following conditions: Small Intestinal Bacterial Overgrowth Syndrome (SIBO).
What interventions are being tested in trial NCT06721884?
The interventions under investigation include: placebo (OTHER), Artemisia Annua Leaf (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06721884?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721884 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06721884's enrollment target sits among peer trials
32 1297th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI